01972nas a2200301   4500000000100000000000100001008004100002260000900043653002700052653003500079653002400114653001600138653002100154100001800175700002000193700001800213700002500231700002500256700002100281700002300302700002600325245014800351856006700499300001100566490000700577520107200584022001401656       2026                            d  c202610aalveolar type II cells10ainduced pluripotent stem cells10ainfluenza A viruses10aoseltamivir10aviral infections1 aLena Gauthier1 aHristina Koceva1 aYann Bachelot1 aRosanne W. Koutstaal1 aPuck B. van Kasteren1 aMarc Thilo Figge1 aChristian Eggeling1 aAlexander Sandy Mosig00aGeneration of an Induced Pluripotent Stem Cell-Derived Alveolar Type II In Vitro Model to Study Influenza A Virus Infection and Drug Treatments  uhttps://onlinelibrary.wiley.com/doi/abs/10.1002/adhm.202405141  ae051410 v153 aInfluenza viruses (IVs) represent a significant global health issue, capable of causing seasonal epidemics and occasional pandemics with substantial morbidity and mortality. The emergence of viral resistance further complicates treatment strategies. In this study, induced pluripotent stem cell-derived human alveolar type II (iAT2) cells are used to model influenza A virus (IAV) infection and to assess antiviral responses. Cultured at an air–liquid interface (ALI) in transwell systems, iAT2 cells recapitulate key features of the alveolar epithelium and support productive IAV replication. Upon infection, iAT2 cells mounted an antiviral transcriptional response and exhibited sensitivity to oseltamivir treatment, consistent with its established in vivo efficacy. Together, these findings highlight the utility of iAT2 cells as a scalable, physiologically relevant in vitro model for influenza research and antiviral drug testing. Future applications may include the evaluation of emerging viral strains and the development of personalized antiviral therapies.  a2192-2659